CRISPR_Logo.jpg
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 16, 2020 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Crspr.jpg
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
November 04, 2020 09:15 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in...
Crspr.jpg
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
October 28, 2020 08:00 ET | CRISPR Therapeutics AG
-Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies- - Received Rare Pediatric...
Crspr.jpg
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
October 21, 2020 07:00 ET | CRISPR Therapeutics AG
-50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR- -Early evidence of dose-dependent responses with CTX110- -Acceptable safety...
Crspr.jpg
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
October 07, 2020 09:26 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has...
Crspr.jpg
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
September 29, 2020 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Crspr.jpg
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
September 22, 2020 09:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the...
Crspr.jpg
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 03, 2020 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Crspr.jpg
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
July 30, 2020 08:00 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Crspr.jpg
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
July 27, 2020 16:30 ET | CRISPR Therapeutics AG
-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- ...